Search This Blog

Labels

T 1673/11 - Swiss type claim in opposition

Change categories?

Can a patent proprietor change a Swiss type claim to a purpose-limited product claim during opposition proceedings? The board finds that the Swiss type claim as granted has a narrower scope than the purpose-limited product claim; changing categories thus infringes A.123(3).

Claim 1 as granted reads:
"The use of human acid alpha glucosidase in the manufacture of a medicament for the treatment of infantile Pompe's disease, wherein the human acid alpha glucosidase is in the 100 to 110 kD form, wherein the medicament is to be administered intravenously, and wherein the treatment is to be continued for at least 4 weeks."

Claim 1 of the main request held allowable by the opposition division reads:
"Human acid alpha glucosidase in the 100 to 110 kD form, for use in the treatment of infantile Pompe's disease, wherein the human acid alpha glucosidase is to be administered intravenously, and wherein the treatment is to be continued for at least 4 weeks."

According to the board, a human acid alpha glucosidase provided with instructions for the use in a treatment other than that of infantile Pompe's disease, would fall under the scope of the purpose-limited product claim if it is used for infantile Pompe's disease.



Reasons for the Decision
1. The appeal is admissible.

Main request - Article 123(3) EPC

2. Claim 1 of the main request is drafted in the format of a purpose-limited product claim as provided for by Article 54(5) EPC ("Human acid alpha glucosidase in the 100 to 110 kD form, for use in the treatment of infantile Pompe's disease, wherein..."), whereas all claims as granted are in the so called "Swiss-type" form ("The use of human acid alpha glucosidase in the manufacture of a medicament for the treatment of infantile Pompe's disease, wherein the human acid alpha glucosidase is in the 100 to 110 kD form, wherein...").

3. Under the EPC 1973, it was established practice that a patent relating to a further medical application of a known medicament could only be granted for a claim directed to the use of a substance or composition for the manufacture of a medicament for a specified therapeutic application (so-called "Swiss-type claim"). This practice was based on decision G 5/83 of the EBA (OJ EPO 1985, 64) which had filled a gap in the legal provisions and extended the notional novelty provided for in Article 54(5) EPC 1973 for the first medical use to further medical use claims when drafted in the above format. The law itself (EPC 1973) did not contain any notional acknowledgement of novelty of a claim directed to a further medical use.

The provisions of Article 54(5) EPC now fill this gap in the former provisions. Article 54(5) EPC provides for purpose-limited product protection for any substance or composition comprised in the state of the art for any specific use in a method referred to in Article 53(c) EPC (see decision G 2/08 of the EBA, OJ EPO 2010, 456, points 5.9, 5.10.2, 6.4 and 6.5).

4. Article 123(3) EPC provides that during opposition proceedings the claims of the European patent may not be amended in such a way as to extend the protection conferred upon grant.

5. In decision G 2/88 (OJ EPO 1990, 93, point 3.3) the Enlarged Board of Appeal noted that there is a clear distinction between the protection which is conferred and the rights which are conferred by a European patent: "The protection conferred by a patent is determined by the terms of the claims (Article 69(1) EPC), and in particular by the categories of such claims and their technical features. (...) In contrast, the rights conferred on the proprietor of a European patent (Article 64(1) EPC) are the legal rights which the law of a designated Contracting State may confer upon the proprietor, for example, as regards what acts of third parties constitute infringement of the patent, and as regards the remedies which are available in respect of any infringement. In other words, in general terms, determination of the 'extent of the protection conferred' by a patent under Article 69(1) EPC is a determination of what is protected, in terms of category plus technical features; whereas the 'rights conferred' by a patent are a matter solely for the designated Contracting States, and are related to how such subject-matter is protected."

It is therefore not appropriate for the board to consider the national laws of the Contracting States in relation to infringement (e.g. the rights of the patent proprietor to sue for indirect or contributory infringement); such national provisions are not relevant when deciding upon the admissibility of an amendment under Article 123(3) EPC. With respect to the question of extension of scope of protection under Article 123(3) EPC, it is instead appropriate to take into account that the protection conferred by a patent is determined by the terms of the claims, and in particular by the categories of the claims and their technical features (T 1780/12 of 30 January 2014, point 13; T 547/08 of 10 March 2011, point 3.2).

6. According to decision G 2/88 (point 4.1) the test to be applied under Article 123(3) EPC is whether the subject-matter defined by the claims is more or less narrowly defined as a result of the amendment. In the case of a change of category of claims, the protection conferred by the categories of claims in the patent as granted must be compared with the protection conferred by the new category of claim introduced by the amendment. This comparison necessarily involves considerations on the extent of protection conferred by a given category of claim. As is evident from decision G 2/88, such considerations are independent of the rights conferred under national law and of infringement.

7. The amendment of the patent as granted according to the main request consists in a change of category of claim 1 from a purpose-limited process claim in the format of a Swiss-type claim in accordance with decision G 5/83 to a purpose-limited product claim in accordance with Article 54(5) EPC. It follows from decision G 2/88 (point 5.1) that it is generally accepted as a principle underlying the EPC that a claim to a particular physical activity (e.g. method, process, use) confers less protection than a claim to the physical entity per se. As a consequence, a purpose-limited process claim confers less protection than a purpose-limited product claim (T 1780/12, supra, point 22, albeit in the context of double patenting; followed by decision T 879/12 of 27 August 2014, point 14; see also T 250/05 of 4 March 2008, point 3.6). Therefore, the change in category of claim 1 of the patent contravenes Article 123(3) EPC.

8. The respondent disagreed with the approach taken in decision T 1780/12 in as far as it was based on a comparison of the claim categories and the principle that a process claim was inherently narrower than a product claim. In the respondent's opinion, such an approach did not take into account the extension of protection by virtue of Article 64(2) EPC and the delimitation of the subject-matter claimed by the technical features. A purpose-limited process claim in the format of a Swiss-type claim was directed to a process of manufacture of a product. According to Article 64(2) EPC the protection conferred by such a process extended to the products directly obtained. Because the manufacturing process in a Swiss-type claim was not limited by any technical feature, the manufacture could not be limiting on the product obtained by it. The medical use as limiting feature was the same whether the claim was drafted in the format of a Swiss-type claim or as a purpose-limited product claim in accordance with Article 54(5) EPC. As a consequence, the protection conferred by both types of claims was the same.

9. The board does not agree. First, the comparison of the the protection conferred by the categories of claims in the patent before amendment with the protection conferred by the new category of claims introduced by amendment is in line with the test set out in decision G 2/88 (see point 5 above). Second, the protection conferred by a Swiss-type claim in accordance with decision G 5/83 and a purpose-limited product claim in accordance with Article 54(5) EPC is not the same even if, for the sake of argument, it is accepted that Article 64(2) EPC is to be taken into account when assessing the extent of protection conferred by a Swiss-type claim (see decision T 1635/09 of 27 October 2010, point 14.2).

9.1 Claim 1 as granted is directed to the use of human acid alpha glucosidase in the 100 to 110 kD form in the manufacture of a medicament for the treatment of infantile Pompe's disease. Inasmuch as this use may be regarded as a manufacturing process, the claim would, pursuant to Article 64(2) EPC, confer protection on the product directly obtained thereby. The board judges that the product directly obtained is the manufactured medicament which contains as an active substance human acid alpha glucosidase in the 100 to 110 kD form and which is packaged and/or provided with instructions for use in the treatment of infantile Pompe's disease. Indeed, in a Swiss-type claim, the medicament is characterised by the functional feature of the specified therapeutic application. Contrary to the respondent's opinion, this implies limitations to the product directly obtained, although the manufacturing steps are characterised by the use of a defined compound only.

9.2 Claim 1 of the main request being drafted as a purpose-limited product claim, on the other hand, confers protection on the human acid alpha glucosidase in the 100 to 110 kD form, whenever it is being used for the treatment of infantile Pompe's disease. Since the claim does not refer to a step of manufacture of a medicament, the product claimed, i.e. the human acid alpha glucosidase in the 100 to 110 kD form, is not limited to a manufactured medicament, packaged and/or with instructions for use in the treatment of infantile Pompe's disease.

9.3 It follows from the above that even if, by virtue of Article 64(2) EPC, the protection conferred by granted claim 1 extended to the product directly obtained by the manufacturing process referred to in said claim, the protection conferred by claim 1 of the main request is broader.

9.4 Nor can the board follow the appellant's argument that since the use limitation of the claims of the main request and of the granted claims was the same, their scope of protection was identical.

The board takes the position that, for example, a medicament containing human acid alpha glucosidase in the 100 to 110 kD form packaged and provided with instructions for the use in a treatment other than that of infantile Pompe's disease is encompassed by the scope of claim 1 of the main request when said medicament is being used for the treatment of infantile Pompe's disease. The protection conferred by granted claim 1 does not encompass such use.

9.5 Consequently, claim 1 of the main request would amend the contested patent in such a way as to extend the protection it confers, contrary to Article 123(3) EPC.

10. Decision T 402/89 of 12 August 1991, on which the respondent relied, concerned the question whether an amendment of a granted product claim to one for a particular, described process for making that product was allowable under Article 123(3) EPC. In the context of this particular type of amendment, which differed from the one considered in G 2/88 (supra), the board elaborated on difficulties in separating the concepts of "protection conferred" on the one hand and "rights conferred" on the other (see point 2 of the decision).

The present board takes the position that the findings in said decision apply to the particular case considered and are not relevant for this decision which concerns the amendment of "Swiss-type" claims as granted to purpose-limited product claims. In view of points 2 to 9 above, the distinction between the terms "protection conferred" and "rights conferred" is not critical for the case at issue and moreover is in line with the distinction made in decision T 402/89.

11. In decision T 795/06 of 18 March 2010, also relied upon by the respondent, the board decided that the amendment of a granted claim directed to the use of botulinum neurotoxins for the preparation of a pharmaceutical for cosmetic treatment to a claim directed to the use of a pharmaceutical comprising botulinum neurotoxins for cosmetic treatment was allowable under Article 123(3) EPC, because by virtue of Article 64(2) EPC and given that the process of manufacture in claim 1 as granted was defined in a broad way, the protection conferred by the granted claim extended to any pharmaceuticals that were the direct products of a manufacturing process using the botulinum neurotoxins; consequently, the protection conferred by the granted claim also extended to the use of said pharmaceuticals.

The situation underlying said decision differs from that of the present one inter alia in that the amended claim under consideration in decision T 795/06 concerned the use of a pharmaceutical comprising certain substances, whereas claim 1 of the present main request is directed to a substance for use. Therefore, decision T 795/06 is not in contradiction to the present decision.

12. In view of the above, the main request is not allowable under Article 123(3) EPC.
 
This decision T 1673/11 (pdf) has European Case Law Identifier: ECLI:EP:BA:2015:T167311.20151020. The file wrapper can be found here. Photo "Oil and Vinegar.jpg" by Sheila Sund obtained via Flickr under CC BY 2.0 license (no changes made).

Comments